title: Peripheral and central nervous system inhibition of 11β-hydroxysteroid dehydrogenase type 1 in man by the novel inhibitor ABT-384.
abstract: ABT-384 is a potent, selective inhibitor of 11-beta-hydroxysteroid dehydrogenase type 1 (HSD-1). One milligram of ABT-384 daily fully inhibited hepatic HSD-1. Establishing the dose that fully inhibits central nervous system (CNS) HSD-1 would enable definitive clinical studies in potential CNS indications. [9,11,12,12-(2)H4] cortisol (D4 cortisol), a stable labeled tracer, was used to characterize HSD-1 inhibition by ABT-384. D4 cortisol and its products were measured in the plasma and cerebrospinal fluid (CSF) of healthy male volunteers during D4 cortisol infusions, for up to 40 h after five daily doses of 1-50 mg ABT-384. Similar procedures were conducted in control subjects who received no ABT-384. Peripheral HSD-1 inhibition was calculated from plasma levels of D4 cortisol and its products. CNS HSD-1 inhibition was characterized from plasma and CSF levels of D4 cortisol and its products. ABT-384 regimens ≥2 mg daily maintained peripheral HSD-1 inhibition ≥88%. ABT-384 1 mg daily maintained peripheral HSD-1 inhibition ≥81%. No CNS formation of D3 cortisol (the mass-labeled product of HSD-1) was detected following ABT-384 ≥2 mg daily, indicating full CNS HSD-1 inhibition by these regimens. Partial CNS HSD-1 inhibition was associated with 1 mg ABT-384 daily. CNS HSD-1 inhibition was characterized by strong hysteresis and increased with maximum post-dose plasma concentration of ABT-384 and its active metabolites. ABT-384 has a wide potential therapeutic window for potential indications including Alzheimer's disease and major depressive disorder. Stable labeled substrates may be viable tools for measuring CNS effect during new drug development for other enzyme targets.
authors: AbbVie, North Chicago, IL, USA. david.a.katz@me.com
authors: D A
authors: DA
authors: Katz
authors: W
authors: W
authors: Liu
authors: C
authors: C
authors: Locke
authors: P
authors: P
authors: Jacobson
authors: D M
authors: DM
authors: Barnes
authors: R
authors: R
authors: Basu
authors: G
authors: G
authors: An
authors: M J
authors: MJ
authors: Rieser
authors: D
authors: D
authors: Daszkowski
authors: F
authors: F
authors: Groves
authors: G
authors: G
authors: Heneghan
authors: A
authors: A
authors: Shah
authors: H
authors: H
authors: Gevorkyan
authors: S S
authors: SS
authors: Jhee
authors: L
authors: L
authors: Ereshefsky
authors: G J
authors: GJ
authors: Marek
mesh_terms: D043205:11-beta-Hydroxysteroid Dehydrogenase Type 1 / Q000037:antagonists & inhibitors*; D000218:Adamantane / Q000031:analogs & derivatives* / Q000494:pharmacology; D000328:Adult; D002490:Central Nervous System / Q000187:drug effects* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D006801:Humans; D006854:Hydrocortisone / Q000097:blood / Q000134:cerebrospinal fluid / Q000378:metabolism*; D006859:Hydrogen; D007554:Isotopes; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000494:pharmacology*
chemical_list: D007554:Isotopes; C584004:N-(5-(aminocarbonyl)tricyclo(3.3.1.13,7)dec-2-yl)-alpha,alpha-dimethyl-4-(5-(trifluoromethyl)-2-pyridinyl)-1-piperazineacetamide; D010879:Piperazines; D006859:Hydrogen; D043205:11-beta-Hydroxysteroid Dehydrogenase Type 1; D000218:Adamantane; D006854:Hydrocortisone
references: Diabetes. 2009 Jan;58(1):39-45
references: 18852327
references: Diabetes. 2006 Mar;55(3):667-74
references: 16505229
references: Endocr Rev. 2004 Oct;25(5):831-66
references: 15466942
references: Neurology. 2001 Feb 13;56(3):408-10
references: 11171913
references: Diabetes. 2004 Aug;53(8):2051-9
references: 15277385
references: Neuropsychopharmacology. 2010 Feb;35(3):623-31
references: 19890267
references: Clin Pharmacol Ther. 2009 May;85(5):506-12
references: 19129751
references: Endocr Rev. 1997 Feb;18(1):135-56
references: 9034789
references: Eur J Clin Pharmacol. 1997;52(2):121-8
references: 9174681
references: Synapse. 2001 Apr;40(1):19-26
references: 11170218
references: J Nucl Med. 2005 Oct;46(10):1618-24
references: 16204711
references: Alzheimers Dement. 2012 Jul;8(4):295-303
references: 22047633
references: Diabetes. 2005 May;54(5):1364-70
references: 15855321
references: Clin Pharmacol Drug Dev. 2013 Apr;2(2):133-51
references: 27121668
references: J Clin Endocrinol Metab. 2005 Jul;90(7):3919-26
references: 15811928
references: Clin Endocrinol (Oxf). 1996 Nov;45(5):605-11
references: 8977758
references: J Clin Endocrinol Metab. 2002 Jan;87(1):277-85
references: 11788660
references: J Steroid Biochem Mol Biol. 1991 Mar;38(3):351-7
references: 2009227